Genetic Changes in Patients With Non-Small Cell Lung Cancer Who Are Receiving Vinorelbine and Gemcitabine Before Surgery

Part of paid clinical trials in Buffalo, New York.

Sponsor
Roswell Park Cancer Institute
Study ID
NCT00057798
Phase
PHASE2
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • gemcitabine hydrochloride — DRUG
  • vinorelbine ditartrate — DRUG
  • cytogenetic analysis — GENETIC
  • loss of heterozygosity analysis — GENETIC
  • microarray analysis — GENETIC
  • conventional surgery — PROCEDURE
  • neoadjuvant therapy — PROCEDURE

Study Details

RATIONALE: Determination of genetic changes in patients with non-small cell lung cancer may help predict the outcome of treatment. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug, and giving them before surgery, may shrink the tumor so that it can be removed during surgery. PURPOSE: Phase II trial to study genetic changes and the effectiveness of combining vinorelbine with gemcitabine before surgery in treating patients who have stage IB, stage II, or stage III non-small cell lung cancer.

Key Dates

Start date
Mar 31, 2000
Status verified
Mar 2011
Primary completion
May 31, 2003
Completion
Jun 30, 2008

Study Design

Enrollment
21 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Locations (1)

FacilityCityStateZIPSite coordinators
Roswell Park Cancer InstituteBuffaloNew York14263-0001-

Find similar trials in Buffalo, NY

By condition
Lung cancer
By specialty
OncologyLung oncologyLung disease
By research site
Roswell Park Cancer Institute· Buffalo, NY

Related Studies